Increased SCD1 activity reduces tumor susceptibility to cell death by ferroptosis [106], and reduction of tumor SCD1 activity is a target of anti-cancer therapies [107], since prognosis is worsened for breast and kidney cancers when tumors overexpress SCD1 [108,109]. This evidence concerns the gene SCD and kidney cancer.